Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which sedation is safer for TAVR? propofol vs dexmedetomidine

NCT ID NCT05462938

Completed Knowledge-focused Sponsor: University of Ioannina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two common sedation drugs, propofol and dexmedetomidine, in 65 older adults undergoing a less invasive heart valve replacement called TAVR. The goal was to see which drug leads to better kidney function, less confusion, and fewer complications after the procedure. Researchers measured kidney markers and delirium at several time points up to 30 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
propofol and dexmedetomidine
What this could lead to
If this study shows one drug is clearly better, it could guide doctors to choose the safer sedation method for TAVR patients, potentially reducing kidney problems and confusion after the procedure.
What could go wrong
This is a small, completed study with only 65 patients, so results may not apply to everyone. The findings are not yet conclusive and need larger trials to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVERSE EVENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis Death Emergence Delirium impaired renal function disease Personal Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVERSE EVENT DEATH POSTOPERATIVE DELIRIUM RENAL FUNCTION DISORDER SATISFACTION

Contacts and locations

Locations

  • Univesity Hospital of Ioannina

    Ioannina, Epirus, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.